DS2 |
Katalog-Nr.GC12008
One-Click Copy Product Info
|
DS2 ist ein selektiver positiver allosterischer Modulator des δ-GABAA-Rezeptors.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 374084-31-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
DS2 is a novel and selective positive allosteric modulator of δ-subunit-containing GABAA receptors. DS2 enhances the function of extrasynaptic δ-GABAA receptors by increasing the maximal response to GABA, while acting via an unknown site to provide receptor subunit selectivity[1-2]. DS2 is used to study the function of extrasynaptic δ-GABAA receptors and their role in stroke recovery[3-4].
In vitro, HEK293 cells stably expressing the human δ subunit were co-incubated with DS2 (1–5μM) and GABA (EC₂₅–₃₅) to measure the current response. DS2 selectively potentiated the current response or fluorescence signal at δ-GABAA receptors (α₄β₁δ and α₄β₃δ)[5]. Mouse thalamic ventrobasal (VB) neurons and cerebellar granule cells (CGCs) were pretreated with DS2 (3–10µM) for 30 seconds before recording in the presence of ambient GABA. DS2 significantly enhanced the tonic inhibitory current mediated by δ-subunit-containing δ-GABAA receptors[6].
In vivo, in the AppNL-F KI AD mouse model aged 12-16 months, DS2 (1-4mg/kg) was administered via intraperitoneal injection once daily for 5 consecutive days. DS2 significantly reduced anxiety-like behaviors and normalized the expression of δ-GABAA receptors[7]. In male C57BL/6J mice after stroke, DS2 (0.1-4mg/kg) was administered via intraperitoneal injection twice, at 1 hour and 24 hours post-stroke. DS2 significantly reduced infarct volume, improved motor function in the grid-walking and cylinder tasks, and lowered the levels of circulating pro-inflammatory cytokines (TNF-α, IL-6, IL-17)[8].
References:
[1] Lee HJ, Absalom NL, Hanrahan JR, et al. A pharmacological characterization of GABA, THIP and DS2 at binary α4β3 and β3δ receptors: GABA activates β3δ receptors via the β3(+)δ(-) interface. Brain Res. 2016 Aug 1;1644:222-30.
[2] Jensen ML, Wafford KA, Brown AR, et al. A study of subunit selectivity, mechanism and site of action of the delta selective compound 2 (DS2) at human recombinant and rodent native GABA(A) receptors. Br J Pharmacol. 2013 Mar;168(5):1118-32.
[3] Jensen NN, Wilhelmsen KS, Jensen MH, et al. Exploring the DS2 Scaffold for GABAA Receptor Modulation: Progress toward the Development of a GABAA δ-Subunit Preferring Negative Allosteric Modulator. J Med Chem. 2026 Feb 26;69(4):3811-3832.
[4] Rostrup F, Falk-Petersen CB, Harpso E K, et al. Structural Determinants for the Mode of Action of Imidazopyridine DS2 at δ-Containing γ-Aminobutyric Acid Type A Receptors. J Med Chem. 2021 Apr 22;64(8):4730-4743.
[5] Falk-Petersen CB, Søgaard R, Madsen KL, et al. Development of a Robust Mammalian Cell-based Assay for Studying Recombinant α4 β1/3 δ GABAA Receptor Subtypes. Basic Clin Pharmacol Toxicol. 2017 Aug;121(2):119-129.
[6] Wafford KA, van Niel MB, Ma QP, et al. Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus. Neuropharmacology. 2009 Jan;56(1):182-9.
[7] Zhang W, Liu T, Li J, et al. Decreased extrasynaptic δ-GABAA receptors in PNN-associated parvalbumin interneurons correlates with anxiety in APP and tau mouse models of Alzheimer's disease. Br J Pharmacol. 2024 Oct;181(20):3944-3975.
[8] Neumann S, Boothman-Burrell L, Gowing EK, et al. The Delta-Subunit Selective GABA A Receptor Modulator, DS2, Improves Stroke Recovery via an Anti-inflammatory Mechanism. Front Neurosci. 2019 Oct 29;13:1133.
| Cell experiment [1]: | |
Cell lines | HEK293 Flp-In™ cells stably expressing the human GABAA receptor δ-subunit (HEK-δ), co-transfected with human α4 and β1/3 subunits |
Preparation Method | HEK-δ cells were cultured in DMEM with GlutaMAX-I supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C, 5% CO₂. For transient expression, cells were co-transfected with plasmids encoding α4 and β1/3 subunits. 2µM and 5µM DS2 were applied with a low concentration of GABA (1µM, GABA EC₂₅–₃₀). |
Reaction Conditions | 2µM and 5µM; immediate measurement. |
Applications | DS2 selectively potentiated the GABA-induced signal at α4β1δ and α4β3δ receptors but had no effect on binary α4β1/3 receptors. In patch clamp electrophysiology, DS2 potentiated the current response to 1µM GABA at α4β1δ receptors. DS2 is characterized as a δ-subunit selective positive allosteric modulator. |
| Animal experiment [2]: | |
Animal models | Adult (2-3 month old) and aged (22 month old) male C57BL/6J mice with a photothrombotically induced focal stroke in the motor cortex |
Preparation Method | For neuroprotection studies, mice received intraperitoneal (i.p.) injections of DS2 (0.1-4mg/kg) or vehicle 1 hour and 24 hours after stroke induction. For recovery studies, treatment with DS2 via subcutaneously implanted osmotic mini-pumps began 3 days post-stroke and continued for 28 days. |
Dosage form | 0.1-4mg/kg; i.p.; two injections (at 1h and 24h post-stroke). |
Applications | DS2 significantly reduced brain infarct volume and improved motor function recovery in grid-walking and cylinder tasks assessed 7 days post-stroke. DS2 also significantly decreased circulating levels of the pro-inflammatory cytokines TNF-α, IL-6, and IL-17 at 3 days post-stroke. When administered with a 3-day delay, DS2 improved recovery in the grid-walking task but not in the cylinder task. The effects were dose-dependent, with higher doses (1 and 4mg/kg) being less effective. |
References: | |
| Cas No. | 374084-31-8 | SDF | |
| Chemical Name | 4-chloro-N-(2-(thiophen-2-yl)imidazo[1,2-a]pyridin-3-yl)benzamide | ||
| Canonical SMILES | ClC1=CC=C(C=C1)C(NC2=C(C3=CC=CS3)N=C4N2C=CC=C4)=O | ||
| Formula | C18H12ClN3OS | M.Wt | 353.83 |
| Löslichkeit | <17.69mg/ml in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8262 mL | 14.1311 mL | 28.2622 mL |
| 5 mM | 565.2 μL | 2.8262 mL | 5.6524 mL |
| 10 mM | 282.6 μL | 1.4131 mL | 2.8262 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)